Mazdutide vs MGF (Mechano Growth Factor)
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
MazdutideAnabolic & IGF
MGF (Mechano Growth Factor)- Summary
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- MGF (Mechano Growth Factor) is a splice variant of IGF-1 that is locally produced in muscle tissue in response to mechanical damage from exercise. It activates muscle satellite cells (stem cells) to proliferate and repair damaged fibers, making it specifically targeted at exercise-induced hypertrophy.
- Half-Life
- ~7 days
- Native MGF: minutes. PEG-MGF: ~3 days
- Admin Route
- SubQ
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- 200–400 mcg
- Frequency
- Once weekly
- 1–2 times per week
- Key Benefits
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Activates muscle satellite cells for repair and growth
- Accelerates recovery from muscle damage
- Synergistic with IGF-1 LR3 (different mechanisms)
- Promotes muscle hypertrophy specifically at exercised muscles
- Faster recovery between training sessions
- Potential for injury repair in connective tissue
- Side Effects
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Muscle soreness (satellite cell activation)
- Injection site irritation
- Hypoglycemia risk (modest, less than IGF-1 LR3)
- Stacks With
- —
- —